RU2215001C2 - Производные бензо(b)тиепин-1,1-диоксидов, способ их получения, лекарственное средство и способ его получения - Google Patents

Производные бензо(b)тиепин-1,1-диоксидов, способ их получения, лекарственное средство и способ его получения Download PDF

Info

Publication number
RU2215001C2
RU2215001C2 RU2001101491/04A RU2001101491A RU2215001C2 RU 2215001 C2 RU2215001 C2 RU 2215001C2 RU 2001101491/04 A RU2001101491/04 A RU 2001101491/04A RU 2001101491 A RU2001101491 A RU 2001101491A RU 2215001 C2 RU2215001 C2 RU 2215001C2
Authority
RU
Russia
Prior art keywords
formula
compounds
ethyl
methyl
butyl
Prior art date
Application number
RU2001101491/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2001101491A (ru
Inventor
Венделин ФРИК (DE)
Венделин Фрик
Альфонс ЭНЗЕН (DE)
Альфонс ЭНЗЕН
Хайнер ГЛОМБИК (DE)
Хайнер Гломбик
Хуберт ХОЙЕР (DE)
Хуберт Хойер
Original Assignee
Авентис Фарма Дойчланд Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма Дойчланд Гмбх filed Critical Авентис Фарма Дойчланд Гмбх
Publication of RU2001101491A publication Critical patent/RU2001101491A/ru
Application granted granted Critical
Publication of RU2215001C2 publication Critical patent/RU2215001C2/ru

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D337/00Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02Seven-membered rings
    • C07D337/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06086Dipeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
RU2001101491/04A 1998-06-10 1999-05-28 Производные бензо(b)тиепин-1,1-диоксидов, способ их получения, лекарственное средство и способ его получения RU2215001C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19825804A DE19825804C2 (de) 1998-06-10 1998-06-10 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19825804.6 1998-06-10

Publications (2)

Publication Number Publication Date
RU2001101491A RU2001101491A (ru) 2003-01-20
RU2215001C2 true RU2215001C2 (ru) 2003-10-27

Family

ID=7870440

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001101491/04A RU2215001C2 (ru) 1998-06-10 1999-05-28 Производные бензо(b)тиепин-1,1-диоксидов, способ их получения, лекарственное средство и способ его получения
RU2001101499/04A RU2220141C2 (ru) 1998-06-10 1999-05-29 Производные бензотиепин-1,1-диоксидов, способ их получения и лекарственное средство

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2001101499/04A RU2220141C2 (ru) 1998-06-10 1999-05-29 Производные бензотиепин-1,1-диоксидов, способ их получения и лекарственное средство

Country Status (26)

Country Link
US (1) US6387944B1 (US06387944-20020514-C00003.png)
EP (2) EP1086092B1 (US06387944-20020514-C00003.png)
JP (2) JP4374426B2 (US06387944-20020514-C00003.png)
KR (2) KR100681721B1 (US06387944-20020514-C00003.png)
CN (2) CN1127497C (US06387944-20020514-C00003.png)
AR (2) AR018634A1 (US06387944-20020514-C00003.png)
AT (2) ATE227715T1 (US06387944-20020514-C00003.png)
AU (2) AU753275B2 (US06387944-20020514-C00003.png)
BR (2) BR9912188B1 (US06387944-20020514-C00003.png)
CA (2) CA2334775C (US06387944-20020514-C00003.png)
CZ (2) CZ297989B6 (US06387944-20020514-C00003.png)
DE (3) DE19825804C2 (US06387944-20020514-C00003.png)
DK (2) DK1086092T3 (US06387944-20020514-C00003.png)
ES (2) ES2182535T3 (US06387944-20020514-C00003.png)
HK (2) HK1036799A1 (US06387944-20020514-C00003.png)
HU (2) HU229761B1 (US06387944-20020514-C00003.png)
ID (2) ID28695A (US06387944-20020514-C00003.png)
IL (1) IL140078A (US06387944-20020514-C00003.png)
NO (1) NO327075B1 (US06387944-20020514-C00003.png)
NZ (1) NZ508681A (US06387944-20020514-C00003.png)
PL (2) PL196074B1 (US06387944-20020514-C00003.png)
PT (2) PT1086092E (US06387944-20020514-C00003.png)
RU (2) RU2215001C2 (US06387944-20020514-C00003.png)
TR (2) TR200003634T2 (US06387944-20020514-C00003.png)
WO (2) WO1999064410A1 (US06387944-20020514-C00003.png)
ZA (2) ZA200007060B (US06387944-20020514-C00003.png)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
PT1345895E (pt) * 2000-12-21 2007-02-28 Sanofi Aventis Deutschland Novas difenilazetidinonas, processo para a sua preparação, fármacos contendo estes compostos e sua utilização para o tratamento de distúrbios do metabolismo lipídico
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
CA2457976A1 (en) * 2001-08-22 2003-03-06 Aventis Pharma Deutschland Gmbh Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP3616635B2 (ja) 2001-09-08 2005-02-02 アストラゼネカ アクチボラグ 高脂質血症の治療のための回腸胆汁酸運搬(ibat)阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US20040138145A1 (en) * 2002-12-12 2004-07-15 Aventis Pharma S.A. Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
DE102006053636B4 (de) * 2006-11-14 2008-09-18 Sanofi-Aventis Deutschland Gmbh Neue mit Cyclohexylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate und deren Verwendung
DE102006053635B4 (de) * 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20100221513A1 (en) * 2008-09-05 2010-09-02 Wisconsin Alumni Research Foundation Self sintering transparent nanoporous thin-films for use in self-cleaning, anti-fogging, anti-corrosion, anti-erosion electronic and optical applications
EP2995317A1 (en) 2010-05-26 2016-03-16 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
DK2637668T3 (en) 2010-11-08 2016-08-29 Albireo Ab Ibat inhibitors for the treatment of liver diseases
KR20210131431A (ko) 2011-10-28 2021-11-02 샤이어 휴먼 지네틱 테라피즈 인크. 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
AU2014228850A1 (en) 2013-03-15 2015-10-29 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
CA3011619C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
EP3664782A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine pellets, oral cholestyramine formulations and use thereof
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
SG11202012151XA (en) 2018-06-20 2021-01-28 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
JP2022519664A (ja) 2019-02-06 2022-03-24 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
KR20210126053A (ko) 2019-02-06 2021-10-19 알비레오 에이비 벤조티아디아제핀 화합물 및 담즙산 조절제로서의 그의 용도
WO2020167958A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
JP2023504645A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202134223A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP4069361B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541A1 (en) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
JP3304093B2 (ja) * 1994-09-13 2002-07-22 モンサント カンパニー 回腸の胆汁酸輸送及びタウロコール酸塩吸収の阻害活性を有する新規ベンゾチエピン類
RU2202549C2 (ru) * 1996-03-11 2003-04-20 Джи. Ди. Сирл Энд Ко. Бензотиепины, фармацевтическая композиция на их основе, способ профилактики или лечения гиперлипидемического состояния
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
CA2337307A1 (en) * 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use

Also Published As

Publication number Publication date
NO20006251D0 (no) 2000-12-08
TR200003634T2 (tr) 2001-06-21
ATE259372T1 (de) 2004-02-15
CA2334773C (en) 2009-05-26
PL344827A1 (en) 2001-11-19
CA2334775A1 (en) 1999-12-16
AR018633A1 (es) 2001-11-28
WO1999064409A2 (de) 1999-12-16
WO1999064409A3 (de) 2000-03-02
DE59908522D1 (de) 2004-03-18
AR018634A1 (es) 2001-11-28
JP2002517490A (ja) 2002-06-18
DK1086113T3 (da) 2004-05-24
PL196074B1 (pl) 2007-12-31
DE19825804A1 (de) 1999-12-16
CZ297989B6 (cs) 2007-05-16
JP3374129B2 (ja) 2003-02-04
HU229761B1 (hu) 2014-06-30
AU4503199A (en) 1999-12-30
ID26876A (id) 2001-02-15
HU228570B1 (en) 2013-04-29
ZA200007060B (en) 2001-07-18
WO1999064410A1 (de) 1999-12-16
HK1036799A1 (en) 2002-01-18
NO20006251L (no) 2001-02-07
BR9912188A (pt) 2001-04-10
EP1086113B1 (de) 2004-02-11
CN1305469A (zh) 2001-07-25
JP2002517491A (ja) 2002-06-18
CA2334773A1 (en) 1999-12-16
KR100681721B1 (ko) 2007-02-15
CN1305487A (zh) 2001-07-25
AU752633B2 (en) 2002-09-26
CN1127497C (zh) 2003-11-12
TR200003632T2 (tr) 2001-04-20
NZ508681A (en) 2002-06-28
ZA200007061B (en) 2001-07-18
PL196057B1 (pl) 2007-11-30
AU4501999A (en) 1999-12-30
ATE227715T1 (de) 2002-11-15
IL140078A (en) 2004-08-31
HK1039490A1 (en) 2002-04-26
BR9911123A (pt) 2006-01-03
ES2182535T3 (es) 2003-03-01
CZ20004592A3 (cs) 2001-04-11
BR9911123B1 (pt) 2010-12-14
ES2215387T3 (es) 2004-10-01
HUP0102256A3 (en) 2002-04-29
EP1086092A1 (de) 2001-03-28
CA2334775C (en) 2009-10-13
US6387944B1 (en) 2002-05-14
HUP0102554A3 (en) 2002-12-28
NO327075B1 (no) 2009-04-20
HUP0102256A1 (hu) 2001-12-28
RU2220141C2 (ru) 2003-12-27
PT1086113E (pt) 2004-06-30
PT1086092E (pt) 2003-03-31
KR100562184B1 (ko) 2006-03-20
PL345901A1 (en) 2002-01-14
IL140078A0 (en) 2002-02-10
DE19825804C2 (de) 2000-08-24
AU753275B2 (en) 2002-10-10
CZ297925B6 (cs) 2007-05-02
KR20010052701A (ko) 2001-06-25
KR20010052682A (ko) 2001-06-25
EP1086113A2 (de) 2001-03-28
HUP0102554A1 (hu) 2001-10-28
JP4374426B2 (ja) 2009-12-02
CN1152039C (zh) 2004-06-02
DE59903411D1 (de) 2002-12-19
DK1086092T3 (da) 2003-03-10
EP1086092B1 (de) 2002-11-13
ID28695A (id) 2001-06-28
CZ20004591A3 (cs) 2001-04-11
BR9912188B1 (pt) 2010-12-14

Similar Documents

Publication Publication Date Title
RU2215001C2 (ru) Производные бензо(b)тиепин-1,1-диоксидов, способ их получения, лекарственное средство и способ его получения
EP0309297B1 (en) Therapeutic peptides
EA002819B1 (ru) Циклическое пептидное соединение и его применение, бициклопептидное соединение, пептидное соединение и его применение, фармацевтическая композиция
NZ206236A (en) 3-(4-(1-carboxyalk-3-yl)-alpha-aminoalkanoyl)-3-azatricyclo-(5.2.1.0 2-6 ) decan-4-ylcarboxylic acids
US4346083A (en) Biologically active amides
AU665676B2 (en) Cyclopeptides and their use as absorption promoters when applied to the mucosa
JP4544746B2 (ja) 置換された1,3−ジアリール−2−ピリド−2−イル−3−(ピリド−2−イルアミノ)プロパノール誘導体、その製造方法、それを含有する医薬およびその使用
HUT73674A (en) Biologically active vasopressin analogues
CA1331131C (en) Cyclic peptides as promoters of absorption on administration onto the mucosa
JP2003512387A (ja) Nk2拮抗薬としての単環式化合物、それら化合物の製法、それら化合物を含有する医薬品組成物
MXPA00012208A (en) BENZO(b)THIEPINE-1,1-DIOXIDE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING THESE COMPOUNDS, AND THEIR USE
KAWAI et al. Preparation and opioid activities of N‐methylated analogs of [D‐Ala2, Leu5] enkephalin
WO1992002545A1 (en) Bombesin antagonists
AU595258B2 (en) Vassopressin antagonists
WO2023214576A1 (ja) Hrasおよびnrasに対して選択的なkras阻害作用を有する環状化合物
HUT72734A (en) Proces for producing bone-resorption-inhibiting cyclic compounds and compositions
GB1596535A (en) Biologically-active peptides
HU184720B (en) Process for the preparation of beta-liptropine hormone fragment peptide derivatives and pharmaceutical compositions containing said compounds as active engredient
WO2002000688A1 (fr) Compose peptidique, compositions pharmaceutiques et medicaments contenant ceux-ci comme principe actif

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150529